Report Year: 2025

Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress

Read More

Receipt of a notification under Article 69 of the Public Offering Act from TFI Allianz Polska S.A. regarding the decrease below the 5% threshold of the total number of votes in the Company

Read More

Posters on preclinical data on RVU305 and Synthetic Lethality Programs presented at the 2025 AACR Annual Meeting

Read More

Conclusion of a grant agreement with the Medical Research Agency

Read More

Decision not to enter into a Grant Agreement with the Medical Research Agency

Read More

Dosing of the first patient in the JASPIS-01 phase II study of dapolsertib (MEN1703/SEL24) for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

Read More

Preclinical data on synthetic lethality programs to be presented at the 2025 AACR Annual Meeting

Read More

Ryvu Therapeutics S.A. Annual Report 2024

Read More

Disclosure of delayed inside information regarding the decision to commence the collective redundancy process in the Company and the commencement of the consultation procedure with representatives of the Company’s employees

Read More

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Read More

Conclusion of funding agreement with the Małopolska Centre for Entrepreneurship

Read More

Recommendation of Ryvu’s project for funding by the Medical Research Agency

Read More

Recommendation of Ryvu’s project for funding by the Medical Research Agency

Read More

Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE

Read More